Cover ImageSALE
Market Research Report

Global Cushing's Syndrome Therapeutics Market 2015-2019

Published by TechNavio (Infiniti Research Ltd.) Product code 318844
Published Content info 69 Pages
Immediate Delivery Available
Price
Back to Top
Global Cushing's Syndrome Therapeutics Market 2015-2019
Published: November 12, 2014 Content info: 69 Pages
Description

About Cushing's Syndrome

Cushing's syndrome is a condition caused by the prolonged exposure to very high levels of cortisol. This can occur because of the consumption of glucocorticoid drugs or diseases that result in excess cortisol, ACTH, and CRH secretion. Harvey Cushing described the pathophysiology of this condition in 1932. It is more common in women than in men. Cushing's syndrome is also known as hypercortisolism, hypercorticism, hyperadrenocorticism, or Itsenko-Cushing syndrome. Some of the common symptoms of Cushing's syndrome are increase in weight, facial acne, cognitive disorders, and vulnerability to superficial fungus infections, growth of a mass around the collarbone or back of the neck, commonly known as the "buffalo hump," and puffy face or "moon face". Other symptoms include sweating, polyuria, and hypertension, dilation of the capillaries, thinning of the skin, red striae, osteoporosis, diabetes mellitus, immune suppression, sleep disturbances, muscle weakness, hirsutism, baldness, and hypocalcemia. Cushing's syndrome can broadly be classified into corticotropin-dependent Cushing's syndrome and corticotropin-independent Cushing's syndrome.

TechNavio's analysts forecast the Global Cushing's Syndrome Therapeutics market to grow at a CAGR of 9.41 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Cushing's Syndrome Therapeutics market for the period 2014-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label, and branded therapies used in the treatment of Cushing's syndrome caused in humans.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Cushing's Syndrome Therapeutics market. In addition, the report discusses the major drivers that influence the growth of the market and also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, the Global Cushing's Syndrome Therapeutics market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global BI and Analytics Platform market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Corcept Therapeutics
  • HRA Pharma
  • Novartis

Other Prominent Vendors

  • Aspireo Pharmaceuticals
  • Cortendo
  • ElexoPharm
  • Ipsen
  • Isis Pharmaceuticals
  • Orphagen Pharmaceuticals
  • Samaritan Pharmaceuticals

Market Driver

  • Presence of Unmet Need
  • For a full, detailed list, view our report

Market Challenge

  • Adverse Effects of Drugs
  • For a full, detailed list, view our report

Market Trend

  • Increase in Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors
Table of Contents
Product Code: IRTNTR4695

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Signifor
    • 04.1.2. Korlym
    • 04.1.3. Ketoconazole HRA

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Disease Overview

    • 07.1.1. Understanding the Disease
    • 07.1.2. Etiology and Pathophysiology
    • 07.1.3. Rate of Incidence and Prevalence
    • 07.1.4. Diagnosis of Cushing's Syndrome
    • 07.1.5. Management of Cushing's Syndrome
    • 07.1.6. Economic Burden due to Cushing's Syndrome

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Class of Drugs

  • 09.1. Glucocorticoid Receptor Antagonist
  • 09.2. Somatostatin Analog
  • 09.3. Cortisol Synthesis Inhibitor
  • 09.4. Others

10. Market Segmentation by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. Market Segmentation by Dosage Form

  • 11.1. Solid
  • 11.2. Liquid

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2014
    • 20.2.1. Novartis
    • 20.2.2. Corcept Therapeutics
    • 20.2.3. HRA Pharma
  • 20.3. Other Prominent Vendors

21. Pipeline Portfolio

  • 21.1. Key Information for the Pipeline Candidates
    • 21.1.1. LCI-699
    • 21.1.2. COR-003
    • 21.1.3. Cabergoline
    • 21.1.4. ISIS-GCCRRx
    • 21.1.5. DG-3173

22. Key Vendor Analysis

  • 22.1. Corcept Therapeutics
    • 22.1.1. Key Facts
    • 22.1.2. Business Overview
    • 22.1.3. Recent Developments
    • 22.1.4. SWOT Analysis
  • 22.2. HRA Pharma
    • 22.2.1. Key Facts
    • 22.2.2. Business Overview
    • 22.2.3. Therapeutic Areas
    • 22.2.4. Business Strategy
    • 22.2.5. Recent Developments
    • 22.2.6. SWOT Analysis
  • 22.3. Novartis
    • 22.3.1. Key Facts
    • 22.3.2. Business Description
    • 22.3.3. Business Segmentation
    • 22.3.4. Revenue by Business Segmentation
    • 22.3.5. Revenue Comparison 2012 and 2013
    • 22.3.6. Sales by Geography
    • 22.3.7. Business Strategy
    • 22.3.8. Key Developments
    • 22.3.9. SWOT Analysis

23. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Etiology of Cushing's Syndrome
  • Exhibit 3: Diagrammatic Representation of Cortisol Secretion and its Feedback Loop
  • Exhibit 4: Causes of Cushing's Syndrome
  • Exhibit 5: Diagnosis Algorithm of Cushing's Syndrome
  • Exhibit 6: Global Overactive Bladder Therapeutics Market 2015-2019 (US$ million)
  • Exhibit 7: Global Cushing's Syndrome Therapeutics Market Segmentation by Class of Drugs
  • Exhibit 8: Global Cushing's Syndrome Therapeutics Market by Class of Drugs 2014
  • Exhibit 9: Global Cushing's Syndrome Therapeutics Market Segmentation by Route of Administration
  • Exhibit 10: Global Cushing's Syndrome Therapeutics Market by Route of Administration 2014
  • Exhibit 11: Global Cushing's Syndrome Therapeutics Market Segmentation by Dosage Form
  • Exhibit 12: Global Cushing's Syndrome Therapeutics Market by Dosage Form 2014
  • Exhibit 13: Global Overactive Bladder Therapeutics Market by Geographical Segmentation 2014
  • Exhibit 14: Global Cushing's Syndrome Therapeutics Market Share Analysis 2014
  • Exhibit 15: Snapshot of Pipeline Drugs 2014
  • Exhibit 16: Study Count of Cushing's Syndrome Clinical Trials
  • Exhibit 17: Study Count of Cushing's Syndrome Clinical Trials
  • Exhibit 18: Novartis AG: Business Segmentation
  • Exhibit 19: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 20: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 21: Novartis AG: Revenue by Geographical Segmentation 2013
  • Exhibit 22: HRA Pharma: Therapeutic Areas
Back to Top